These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19895944)

  • 21. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-hospital initiation of statin therapy in acute coronary syndromes: maximizing the early and long-term benefits.
    Fonarow GC
    Chest; 2005 Nov; 128(5):3641-51. PubMed ID: 16304326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease.
    Patel PJ; Khera AV; Jafri K; Wilensky RL; Rader DJ
    J Am Coll Cardiol; 2011 Nov; 58(20):2068-75. PubMed ID: 22051328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relation of high-density lipoprotein cholesterol:apolipoprotein a-I ratio to progression of coronary atherosclerosis in statin-treated patients.
    Mani P; Uno K; St John J; Tuzcu EM; Nissen SE; Nicholls SJ
    Am J Cardiol; 2014 Sep; 114(5):681-5. PubMed ID: 25030535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease.
    Arca M; Montali A; Valiante S; Campagna F; Pigna G; Paoletti V; Antonini R; Barillà F; Tanzilli G; Vestri A; Gaudio C
    Am J Cardiol; 2007 Nov; 100(10):1511-6. PubMed ID: 17996510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Residual lipid profile in recurrent ischemic cardiopathy].
    Millán J; Pedro-Botet J; Muñoz A; Corbella E; Mangas A; Zúñiga M; Hernández-Mijares A; Pintó X
    Med Clin (Barc); 2012 Mar; 138(6):238-41. PubMed ID: 21429535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosuvastatin calcium in acute coronary syndromes.
    Aggarwal RK; Showkathali R
    Expert Opin Pharmacother; 2013 Jun; 14(9):1215-27. PubMed ID: 23574635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonoptimal high-density lipoprotein cholesterol levels are highly prevalent in patients presenting with acute coronary syndromes and well-controlled low-density lipoprotein cholesterol levels.
    Felix-Getzik EM; Kuvin JT; Karas RH
    J Clin Lipidol; 2010; 4(4):265-71. PubMed ID: 21122659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk.
    Jafri H; Alsheikh-Ali AA; Karas RH
    Ann Intern Med; 2010 Dec; 153(12):800-8. PubMed ID: 21173414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should low high-density lipoprotein cholesterol (HDL-C) be treated?
    Toth PP; Barylski M; Nikolic D; Rizzo M; Montalto G; Banach M
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):353-68. PubMed ID: 24840264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome.
    Rosenson RS; Brewer HB; Rader DJ
    Circ Res; 2014 Jun; 114(12):1880-9. PubMed ID: 24902972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
    Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
    Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-density lipoprotein metabolism: potential therapeutic targets.
    Davidson MH; Toth PP
    Am J Cardiol; 2007 Dec; 100(11 A):n32-40. PubMed ID: 18047851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?
    Tardif JC
    J Clin Lipidol; 2010; 4(5):399-404. PubMed ID: 21122683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22).
    Ray KK; Morrow DA; Shui A; Rifai N; Cannon CP
    Am J Cardiol; 2006 Oct; 98(7):861-5. PubMed ID: 16996863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.
    Lim S; Park YM; Sakuma I; Koh KK
    Int J Cardiol; 2013 Jun; 166(1):8-14. PubMed ID: 22503572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HDL as a target in the treatment of atherosclerotic cardiovascular disease.
    Linsel-Nitschke P; Tall AR
    Nat Rev Drug Discov; 2005 Mar; 4(3):193-205. PubMed ID: 15738977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.